Rockville, Maryland — October 6, 2026: The non-invasive diagnostic tests market is set to expand from USD 1.3 billion in 2026 to USD 3.8 billion by 2036, advancing at an 11.3% CAGR during the forecast period. The market is expected to generate an absolute dollar opportunity of USD 2.5 billion as hospitals and laboratories increasingly adopt diagnostic approaches that can provide clinically useful information without tissue removal or invasive access.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
A key growth factor is the rising preference for tests that can replace specific invasive procedures while still supporting clear clinical decisions. Liquid biopsy and cell-free DNA testing are gaining relevance in oncology, while AI-supported imaging and image-sharing tools are helping radiology teams manage diagnostic workloads. Repeated monitoring is another important use case, particularly where non-invasive methods can help physicians track cancer or long-term diseases without requiring repeated invasive procedures.
Imaging Diagnostics leads the test-type segment with a 25.0% share of 2026 demand. Its position reflects the established use of CT, MRI and ultrasound in hospital diagnosis without tissue removal. Next-Generation Sequencing (NGS) also accounts for 25.0% of technology demand, while Oncology represents 25.0% of application demand as non-invasive testing supports cancer assessment, biomarker selection, treatment monitoring and recurrence evaluation.
Germany is forecast to register the strongest country-level growth at 15.5% CAGR through 2036, supported by university hospitals, specialist laboratories and improved data sharing across care providers. Brazil follows at 14.4%, with wider screening access and referral networks supporting diagnostic use across a geographically broad healthcare system. The USA is projected to advance at 13.2%, driven by AI-enabled imaging and molecular diagnostics within large health systems.
Competitive activity includes F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG and GE HealthCare Technologies Inc. Roche and Abbott offer broad diagnostic portfolios, while Siemens Healthineers and GE HealthCare strengthen imaging-led diagnostic pathways.
As diagnostic providers connect imaging, molecular testing and follow-up care into defined clinical pathways, the non-invasive diagnostic tests market is positioned for substantial expansion through 2036. The full Fact.MR report provides detailed market sizing, segment analysis, country forecasts and competitive intelligence.
Explore More Related Studies Published by Fact.MR Research
Acute Coronary Syndrome Market
Acute Care Needleless Connectors Market
About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
– Contact Us –
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | [email protected]
